Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

Drug majors Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (LSE: AZN) have reportedly decided to stop marketing their diabetes drug Forxiga (dapagliflozin) in Germany, having failed to reach agreement on pricing of the drug with the country’s regulatory authorities.

Anglo-Swedish AstraZeneca has so far failed to respond to a request from The Pharma Letter for comment. However, according to a report from Bloomberg, the companies issued a joint statement noting: “The product will continue to be available by prescription until the current supply in the market is exhausted. AstraZeneca and Bristol-Myers Squibb will reassess the decision to stop supplying Forxiga in Germany once the arbitration process is completed.”

IQWiG found no “added benefit” for Forxiga